Pentixapharm

About:

Pentixapharm develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair.

Website: https://www.pentixapharm.com/

Top Investors: Eckert Life Science Accelerator

Description:

PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers. Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System (CNS) Lymphoma while supporting proof-of-concept studies in various other indications.